Non-alcoholic steatosis and steatohepatitis - Editorial;Nealkoholová steatóza a steatohepatitida - Editorial

Vnitrni Lekarstvi

Volumn 56, Issue 3, 2010, Pages 173-175

  Bruha R ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; DISEASE COURSE; DYSLIPIDEMIA; EDITORIAL; FATTY LIVER; HEPATITIS; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PROGNOSIS;

FATTY LIVER; HUMANS; METABOLIC SYNDROME X;

EID: 77950971154     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
2. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317.
3. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007; 133: 1814-1820.
4. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver dinase: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850. (Pubitemid 33641605)
5. Lewis GF, Carpentier A, Adeli K et al. Disordered fat storage and mobilisation in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229. (Pubitemid 34299024)
6. Day C, James O Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
7. Diehl AM, Li ZP, Lin HZ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-306.
8. Hui J, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alfa or adiponectin? Hepatology 2004; 40: 19-22.
9. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
10. Caldwell SH, Oelsner DH, Lezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
11. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3: 1260-1268.
12. Cortez-Pinto H, Baptista A, Camil E et al. Nonalcoholic steatohepatitis clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-179.
13. Dousa M, Zima T, Bruha R et al. Sensitivity and specificity of CDT in the evaluation of alcohol abuse in cirrhotic patients. Gut 2006; 55 (Suppl. No V): A 307.
14. Dunn W, Angulo P, Sanderson S et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006; 131: 1057-1063. (Pubitemid 44498704)
15. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
16. Bugianesi E, Manzini P, D'Antico S et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-187.
17. Loria P, Lonardo A, Leonardi F et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003; 48: 2173-2181. (Pubitemid 38037305)
18. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistence and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
20. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873. (Pubitemid 46489550)
21. Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
22. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107. (Pubitemid 27357062)
23. Bellentani S, Dalle Grave R, Suppini A et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008; 47: 746-754. (Pubitemid 351280743)
24. Angelico F, Burattin M, Alessandri C et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007: CD005166.
25. Capanni M, Calella F, Biagini MR et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-1151.